Business Description
LadRx Corp
NAICS : 325414
SIC : 2836
ISIN : US2328286081
Description
LadRx Corp operates as a biopharmaceutical research and development company in the healthcare sector of the United States. It is focused on the discovery, research, and clinical development of novel anti-cancer drug candidates that employ novel linker technologies to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor. The company develops Aldoxorubicin, which is meant to cure soft tissue sarcoma, a kind of tumor. It also develops Arimoclomol which is in development in Niemann Pick disease Type C (NPC) and Gaucher disease.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.68 | |||||
| Equity-to-Asset | -23.7 | |||||
| Debt-to-Equity | -0.02 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 26.4 | |||||
| 3-Year EPS without NRI Growth Rate | 31.7 | |||||
| 3-Year Book Growth Rate | -79.3 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 25.95 | |||||
| 9-Day RSI | 24 | |||||
| 14-Day RSI | 25.15 | |||||
| 6-1 Month Momentum % | -38.46 | |||||
| 12-1 Month Momentum % | 183.18 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.04 | |||||
| Quick Ratio | 0.04 | |||||
| Cash Ratio | 0.03 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -10.7 | |||||
| Shareholder Yield % | 31.14 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROA % | -162.27 | |||||
| ROIC % | -6704.55 | |||||
| ROC (Joel Greenblatt) % | -14099.26 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | 0.45 | |||||
| EV-to-EBITDA | 0.45 | |||||
| EV-to-FCF | 0.57 | |||||
| Earnings Yield (Greenblatt) % | 222.22 | |||||
| FCF Yield % | -968.35 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:LADX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
LadRx Corp Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -5.79 | ||
| Beta | 1.14 | ||
| Volatility % | 65.72 | ||
| 14-Day RSI | 25.15 | ||
| 14-Day ATR ($) | 0.12832 | ||
| 20-Day SMA ($) | 1.13105 | ||
| 12-1 Month Momentum % | 183.18 | ||
| 52-Week Range ($) | 0.5 - 3.5 | ||
| Shares Outstanding (Mil) | 0.5 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
LadRx Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
LadRx Corp Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
LadRx Corp Frequently Asked Questions
What is LadRx Corp(LADX)'s stock price today?
The current price of LADX is $0.60. The 52 week high of LADX is $3.50 and 52 week low is $0.50.
When is next earnings date of LadRx Corp(LADX)?
The next earnings date of LadRx Corp(LADX) is 2025-02-14 Est..
Does LadRx Corp(LADX) pay dividends? If so, how much?
LadRx Corp(LADX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers